New study aims to stop CMV in kidney transplants

NCT ID NCT07203664

Not yet recruiting Disease control Sponsor: Hospital Universitario La Paz Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two different drug combinations to prevent cytomegalovirus (CMV) infection in kidney transplant patients who are at high risk. Thirty adults who are CMV-positive before transplant will receive either tacrolimus plus mTOR inhibitors with early antiviral treatment, or tacrolimus plus mycophenolic acid with standard preventive antivirals. The goal is to see which strategy better prevents CMV disease and monitors immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tacrolimus, mTOR inhibitors, mycophenolic acid, valganciclovir
What this could lead to: If successful, this could point toward a more effective CMV prevention strategy for kidney transplant patients, reducing infection and complications.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to all patients. The study is not yet recruiting, and the interventions carry risks like infection or organ rejection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure cytomegalovirus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EVALUATE THE EFFECTIVENESS OF CMV PREVENTION STRATEGIES IN KIDNEY TRANSPLANT RECIPIENTS

Contacts and locations

Locations

Hospital Universitario La Paz, Pº de la Castellana, 261 (Servicio de Nefrologia)

Madrid, Madrid, 28046, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.